Sign In
Buy BCDA
$0.82
+0.0531 (+6.89%)
At Close: Jul 31, 2026
BioCardia, Inc. (BCDA) Q2 2025 Earnings Call Transcript
08:37pm, Monday, 11'th Aug 2025
BioCardia, Inc. (NASDAQ:BCDA ) Q2 2025 Earnings Conference Call August 11, 2025 7:00 AM ET Company Participants David McClung - Chief Financial Officer Miranda Peto Benvenuti - Corporate Participant P
BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results
09:15am, Monday, 11'th Aug 2025
SUNNYVALE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,
BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025
03:18pm, Wednesday, 06'th Aug 2025
SUNNYVALE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,
SUNNYVALE, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary di
BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025
08:30am, Wednesday, 21'st May 2025
SUNNYVALE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, t
BioCardia, Inc. (BCDA) Q1 2025 Earnings Call Transcript
07:40pm, Wednesday, 14'th May 2025
Start Time: 16:30 January 1, 0000 5:01 PM ET BioCardia, Inc. (NASDAQ:BCDA ) Q1 2025 Earnings Conference Call May 14, 2025, 16:30 PM ET Company Participants Peter Altman - President and CEO David McClu
BioCardia Reports First Quarter 2025 Business Highlights and Financial Results
04:05pm, Wednesday, 14'th May 2025
SUNNYVALE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, t
BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025
04:28pm, Friday, 09'th May 2025
SUNNYVALE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, t
Insider Buying Surges in May. Especially These 5 Stocks
10:23am, Wednesday, 07'th May 2025
The Securities Act of 1934 established many of the US rules for the securities market in the aftermath of the 1929 Stock Market Crash that ushered in The Great Depression.
BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study
09:15am, Friday, 11'th Apr 2025
CardiAMP HF II is Evaluating the CardiAMP™ Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction and Elevated Markers of Cardiac Stress
BioCardia, Inc. (BCDA) Q4 2024 Earnings Call Transcript
11:30pm, Monday, 31'st Mar 2025
BioCardia, Inc. (NASDAQ:BCDA ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Miranda Peto - Investor Relations Peter Altman - President and CEO David McClung - Chief
BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today
01:39pm, Monday, 31'st Mar 2025
SUNNYVALE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary dise
BioCardia Reports 2024 Business Highlights and Financial Results
04:30pm, Wednesday, 26'th Mar 2025
SUNNYVALE, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,
BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025
08:30am, Friday, 21'st Mar 2025
SUNNYVALE, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,
BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System
09:15am, Monday, 10'th Mar 2025
SUNNYVALE, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary dis
